Head-to-head · WeighScore
FMmeds vs PlushCare
The verdict
PlushCare takes it — 74.5/100 to 63.2/100.
PlushCare grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Established virtual primary-care telehealth platform (subsidiary of Transcarent, Inc., a Delaware corporation, alongside Accolade, 2nd.MD, and 98point6 by Transcarent).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FMmeds | PlushCare |
|---|---|---|
| WeighScore | 63.2/100 | 74.5/100 |
| Grade | C | C |
| Scorecard rank | #257 | #63 |
| Semaglutide | $225/mo (all doses, compounded) | $149/mo (starting dose, compounded) |
| Tirzepatide | $265/mo (all doses, compounded) | $399/mo (starting dose, compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #257 · C
Strengths
- All 50 states plus DC covered, stated in the Terms
- Operating LLC and full Manhattan Beach, CA address disclosed
- Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
- Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
- Flat pricing across all dose strengths — no dose-escalation surcharge
Where it loses points
- Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
- Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
- Clinical network not separately named
- LegitScript Certified, but the specific ID isn't shown
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #63 · C
Strengths
- Available in all 50 states
- Appointments with US board-certified physicians, not nurse practitioners only
- Virtual primary care — the same doctor can manage GLP-1s alongside other health needs
- Owned by Transcarent, a venture-backed health platform with a named corporate parent
Where it loses points
- Facing a California class action alleging deceptive subscription enrollment and unauthorized charges after cancellation
- GLP-1 prescribing is up to the clinician at the visit — not guaranteed at signup
- BBB complaints center on the membership cancellation process
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.